1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 03 NOVEMBER 2014

CNS Drug News 03 NOVEMBER 2014

  • November 2014
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Preventive Migraine Treatment: A Significant Commercial Opportunity
Industry Brief - Genervon Reports GM6 Phase IIa Trial Results In ALS/PD
Industry Brief - Additional ADS-5102 Phase III Trial Initiated In PD Patients With LID
Industry Brief - Astellas/CoMentis To End Alzheimer's Collaboration
Industry Brief - TWi Receives FDA Donepezil Approval
Industry Brief - Results From Two Phase III Studies Added To Aubagio's US Label
Industry Brief - Laquinimod Clinical Development Programme Expanded
Industry Brief - First Patient Enrolled In Vatelizumab Phase II RRMS Trial
Industry Brief - FDA Responds To Antisense's IND Application For ATL1102 Phase IIb MS Trial
Industry Brief - Breckenridge/Natco Gain US Armodafinil Tentative Approval
Industry Brief - Mundipharma Receives Positive CHMP Opinion For Targin In RLS
Industry Brief - GSK/SDP To Terminate Paxil CR Co-Promotion In Japan
Industry Brief - Health Canada Approves Trintellix For Adults With MDD
Industry Brief - ex scientia/Sunovion Partner To Research New Medicines For Psychiatric Disorders
Industry Trend Analysis - Aripiprazole Lauroxil Has Potential To Fuel Future Growth For Alkermes
Industry Brief - Alexza/Ferrer Expand Partnership For Adasuve
Industry Brief - Actavis Initiates Methylphenidate Patent Challenge
Industry Trend Analysis - Pfizer's Embeda Taps Into Growing Need For Abuse-Deterrent Opioids
Industry Brief - Zogenix/Purdue Exchange Waivers Of Regulatory Exclusivity For ER Hydrocodone Products
Industry Brief - Pivotal Phase III Results Published From AVP-825 Acute Migraine Study
Industry Brief - Acura Provides Update On Hydrocodone With Acetaminophen Tablet Development
Industry Brief - Orexo Submits Application To FDA For Expanded Zubsolv Label
Industry Brief - Bunavail Commercially Available In US
Industry Trend Analysis - BDSI Targets Further Opioid-Dependence Market Penetration With Long-Lasting Injectable
Industry Brief - FDA Grants Eisai's sNDA For Banzel Priority Review
Industry Brief - FDA Accepts Fycompa sNDA As Adjunctive Treatment Of PGTC Seizures
Industry Brief - GW's Epidiolex Receives Orphan Designation From EMA For Dravet Syndrome
Industry Brief - Positive Zonegran Results In Pivotal Extension Study
Industry Brief - Lundbeck Receives Carbella CRL From FDA
Industry Brief - Vimpat Phase III Study Meets Primary Endpoint In Japanese/Chinese POS Patients
Industry Brief - GW Begins Phase II/III Trial Of Epidiolex In Dravet Syndrome
Industry Brief - Contrave Available In US Pharmacies
Industry Brief - Neurocrine Initiates Phase III Study Of VMAT2 Inhibitor In TD
Industry Brief - SAGE-547 Phase IIa Trial Initiated In Essential Tremor
Industry Brief - FDA Grants ODD To Ultragenyx' Triheptanoin
Industry Brief - Neurocrine Receives Breakthrough Therapy Designation For NBI-98854 In TD
Industry Brief - Auspex Initiates Second Phase III Trial For SD-809 In TD
Industry Trend Analysis - Shire/AbbVie Combination Now Unlikely
Industry Brief - AbbVie/Shire Agree To Terminate Proposed Merger
Industry Brief - Therapix Signs Non-Binding Agreement To Acquire Dekel Pharmaceuticals
Industry Brief - Forward Pharma Prices IPO
Industry Brief - Relmada Adds USD15mn In Capital To Expedite Development Of Pain Drugs
Industry Brief - Zogenix Acquires UK-Based Brabant Pharma

Table Of Contents

CNS Drug News 03 NOVEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.